29 October 2014 in Nature Communications
The incidence of renal cell carcinoma (RCC) is increasing worldwide, and its prevalence is particularly high in some parts of Central Europe. Here we undertake whole-genome and transcriptome sequencing of clear cell RCC (ccRCC), the most common form of the disease, in patients from four different European countries with contrasting disease incidence to explore the underlying genomic architecture of RCC. Our findings support previous reports on frequent aberrations in the epigenetic machinery and PI3K/mTOR signalling, and uncover novel pathways and genes affected by recurrent mutations and abnormal transcriptome patterns including focal adhesion, components of extracellular matrix (ECM) and genes encoding FAT cadherins. Furthermore, a large majority of patients from Romania have an unexpected high frequency of A:T>T:A transversions, consistent with exposure to aristolochic acid (AA). These results show that the processes underlying ccRCC tumorigenesis may vary in different populations and suggest that AA may be an important ccRCC carcinogen in Romania, a finding with major public health implications.
1 May 2013 in European Journal of Cancer
3 September 2012 in BJU International
FCfor the Bladder Cancer Research Consortium
for the Bladder Cancer Research Consortium
+22
Study Type – Therapy (case series) Level of Evidence 4 What's known on the subject? and What does the study add? Outcomes after disease recurrence in patients with urothelial carcinoma of the bladder treated with radical cystectomy are variable, but the majority of patients die from the disease within 2 years after disease recurrence. Knowledge about prognostic factors that may influence survival after disease recurrence is limited. We found that outcomes after disease recurrence in patients with urothelial carcinoma of the bladder are significantly affected by common clinicopathological factors. In addition, a shorter time from surgery to disease recurrence is significantly associated with poor outcomes. These factors should be considered when scheduling salvage chemotherapy protocols/clinical trials. OBJECTIVE: To describe the natural history following disease recurrence after radical cystectomy (RC) and to identify prognostic factors that influence cancer‐specific survival with special focus on time from RC to disease recurrence. METHODS: We identified 1545 patients from 16 international institutions who experienced disease recurrence after RC and bilateral lymphadenectomy. None of the patients received preoperative chemotherapy; 549 patients received adjuvant chemotherapy. A multivariable Cox regression model addressed time to cancer‐specific mortality after disease recurrence. RESULTS: The median cancer‐specific survival time after disease recurrence was 6.9 months (95% CI 6.3–7.4). Overall, 1254 of 1545 patients died from urothelial carcinoma of the bladder and 47 patients died from other causes. The actuarial cancer‐specific survival estimate at 12 months after disease recurrence was 32%. On multivariable analysis, non‐organ‐confined tumour stages (hazard ratio [HR] 1.38, P = 0.002), lymph node metastasis (HR 1.25, P < 0.001), positive soft tissue surgical margin (HR 1.32, P = 0.002), female gender (HR 1.21, P = 0.003), advanced age (HR 1.16, P < 0.001) and a shorter interval from surgery to disease recurrence ( P < 0.001) were significantly associated with cancer‐specific mortality. The adjusted risk of death from cancer within 1 year after disease recurrence for patients who recurred 6, 12 and 24 months after surgery was 70%, 64% and 60%, respectively. CONCLUSIONS: Over two‐thirds of patients who experience disease recurrence of urothelial carcinoma of the bladder after RC die within 12 months. Common clinicopathological factors are strongly associated with cancer‐specific mortality. A shorter time from surgery to disease recurrence is significantly associated with poor outcomes. Accurate risk stratification could help in patient counselling and decision‐making regarding salvage treatment.
21 June 2012 in BJU International
What's known on the subject? and What does the study add?: Little is known on the association between obesity and urothelial carcinoma of the bladder ( UCB ). Most studies have shown that higher body mass index ( BMI ) is associated with higher rates of perioperative complications. Only one study specifically investigated obesity and bladder cancer‐specific outcomes and reported no significant association between higher BMI and disease‐specific survival in patients with UCB treated with radical cystectomy. However, that study was limited by its small sample size and a high rate of preoperative therapies. In contrast to the only previous study evaluating the association of BMI with oncological outcomes in UCB , we found that obesity ( BMI ≥30 kg/m 2 ) was associated with features of biologically aggressive UCB and clinical outcomes after radical cystectomy and, even when adjusting for the effects of standard clinicopathological features, obesity remained an independent predictor of cancer recurrence, cancer‐specific mortality and overall mortality. Objective: To investigate the association between body mass index ( BMI ) and oncological outcomes in patients after radical cystectomy ( RC ) for urothelial carcinoma of the bladder ( UCB ) in a large multi‐institutional series. Patients and Methods: Data were collected from 4118 patients treated with RC and pelvic lymphadenectomy for UCB . Patients receiving preoperative chemotherapy or radiotherapy were excluded. Univariable and multivariable models tested the effect of BMI on disease recurrence, cancer‐specific mortality and overall mortality. BMI was analysed as a continuous and categorical variable (<25 vs 25–29 vs ≥30 kg/m 2 ). Results: Median BMI was 28.8 kg/m 2 (interquartile range 7.9); 25.3% had a BMI <25 kg/m 2 , 32.5% had a BMI between 25 and 29.9 kg/m 2 , and 42.2% had a BMI ≥30 kg/m 2 . Patients with a higher BMI were older ( P < 0.001), had higher tumour grade ( P < 0.001), and were more likely to have positive soft tissue surgical margins ( P = 0.006) compared with patients with lower BMI . I n multivariable analyses that adjusted for the effects of standard clinicopathological features, BMI >30 was associated with higher risk of disease recurrence (hazard ratio ( HR ) 1.67, 95% confidence interval ( CI ) 1.46–1.91, P < 0.001), cancer‐specific mortality ( HR 1.43, 95% CI 1.24–1.66, P < 0.001), and overall mortality ( HR 1.81, CI 1.60–2.05, P < 0.001). Themain limitation is the retrospective design of the study. Conclusions: Obesity is associated with worse cancer‐specific outcomes in patients treated with RC for UCB . Focusing on patient‐modifiable factors such as BMI may have significant individual and public health implications in patients with invasive UCB .
23 March 2017 in Scientific Reports
Recent genomic studies of sporadic clear cell renal cell carcinoma (ccRCC) have uncovered novel driver genes and pathways. Given the unequal incidence rates among men and women (male:female incidence ratio approaches 2:1), we compared the genome-wide distribution of the chromosomal abnormalities in both sexes. We observed a higher frequency for the somatic recurrent chromosomal copy number variations (CNVs) of autosomes in male subjects, whereas somatic loss of chromosome X was detected exclusively in female patients (17.1%). Furthermore, somatic loss of chromosome Y (LOY) was detected in about 40% of male subjects, while mosaic LOY was detected in DNA isolated from peripheral blood in 9.6% of them, and was the only recurrent CNV in constitutional DNA samples. LOY in constitutional DNA, but not in tumor DNA was associated with older age. Amongst Y-linked genes that were downregulated due to LOY, KDM5D and KDM6C epigenetic modifiers have functionally-similar X-linked homologs whose deficiency is involved in ccRCC progression. Our findings establish somatic LOY as a highly recurrent genetic defect in ccRCC that leads to downregulation of hitherto unsuspected epigenetic factors, and suggest that different mechanisms may underlie the somatic and mosaic LOY observed in tumors and peripheral blood, respectively.